Activin and Inhibin

Bomedemstat (IMG-7289) dihydrochloride is an orally active and irreversible lysine-specific demethylase 1 ( LSD1 ) inhibitor. Bomedemstat dihydrochloride can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat

Bomedemstat (IMG-7289) ditosylate is an orally active and irreversible lysine-specific demethylase 1 ( LSD1 ) inhibitor. Bomedemstat ditosylate can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat ditosylate shows

Bomedemstat (IMG-7289) ditosylate is an orally active and irreversible lysine-specific demethylase 1 ( LSD1 ) inhibitor. Bomedemstat ditosylate can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat ditosylate shows

Bomedemstat (IMG-7289) ditosylate is an orally active and irreversible lysine-specific demethylase 1 ( LSD1 ) inhibitor. Bomedemstat ditosylate can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat ditosylate shows

Bomedemstat (IMG-7289) hydrochloride is an orally active and irreversible lysine-specific demethylase 1 ( LSD1 ) inhibitor. Bomedemstat hydrochloride can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat hydrochloride

Bomedemstat (IMG-7289) hydrochloride is an orally active and irreversible lysine-specific demethylase 1 ( LSD1 ) inhibitor. Bomedemstat hydrochloride can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat hydrochloride

Bomedemstat (IMG-7289) hydrochloride is an orally active and irreversible lysine-specific demethylase 1 ( LSD1 ) inhibitor. Bomedemstat hydrochloride can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat hydrochloride

Bortezomib-d 8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor , and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle,

BPDBA is a selective and noncompetitive betaine/GABA transporter ( BGT-1 ) inhibitor with IC 50 s of 20 μM and 35 μM against human BGT-1 and mouse GAT2, respectively.In VivoBPDBA is predicted to have excellent oral absorption and blood brain barrier

BPDBA is a selective and noncompetitive betaine/GABA transporter ( BGT-1 ) inhibitor with IC 50 s of 20 μM and 35 μM against human BGT-1 and mouse GAT2, respectively.In VivoBPDBA is predicted to have excellent oral absorption and blood brain barrier

BPDBA is a selective and noncompetitive betaine/GABA transporter ( BGT-1 ) inhibitor with IC 50 s of 20 μM and 35 μM against human BGT-1 and mouse GAT2, respectively.In VivoBPDBA is predicted to have excellent oral absorption and blood brain barrier

BPDBA is a selective and noncompetitive betaine/GABA transporter ( BGT-1 ) inhibitor with IC 50 s of 20 μM and 35 μM against human BGT-1 and mouse GAT2, respectively.In VivoBPDBA is predicted to have excellent oral absorption and blood brain barrier